Expert Review of Anti-infective Therapy最新文献

Diagnostic and clinical management of Candida auris infections in immunocompromised patients. 免疫功能低下患者耳念珠菌感染的诊断和临床管理。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-16 DOI: 10.1080/14787210.2025.2505567

Brunella Posteraro, Terenzio Cosio, Riccardo Torelli, Elena De Carolis, Carlotta Magrì, Patrizia Posteraro, Giulia De Angelis, Maurizio Sanguinetti

{"title":"Diagnostic and clinical management of Candida auris infections in immunocompromised patients.","authors":"Brunella Posteraro, Terenzio Cosio, Riccardo Torelli, Elena De Carolis, Carlotta Magrì, Patrizia Posteraro, Giulia De Angelis, Maurizio Sanguinetti","doi":"10.1080/14787210.2025.2505567","DOIUrl":"10.1080/14787210.2025.2505567","url":null,"abstract":"Introduction: Candida (Candidozyma) auris is an emerging fungal pathogen that poses a significant threat to immunocompromised patients. Its high mortality rates, resistance to multiple antifungal classes, and ability to spread rapidly in healthcare settings underscore the need for timely and accurate diagnosis to guide effective clinical management.Areas covered: This special report provides an updated overview of C. auris infections in immunocompromised hosts. It discusses current phenotypic and molecular diagnostic tools, antifungal susceptibility testing methods, and infection control strategies. Emerging therapies, including investigational antifungals and combination regimens, are also examined in light of evolving resistance patterns and clinical challenges.Expert opinion: Despite notable advances in diagnostics and treatment, major obstacles remain in the clinical management of C. auris, particularly in vulnerable populations. Barriers to guideline implementation, lack of standardized screening protocols, and limited access to novel antifungal agents continue to hinder effective response. Future efforts should focus on expanding diagnostic capacity, developing innovative therapies, and implementing targeted surveillance strategies to reduce the global burden of C. auris.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":4.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of potential combinations therapies with ceftriaxone as a treatment for gonorrhea. 头孢曲松作为淋病治疗的潜在联合疗法综述。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-15 DOI: 10.1080/14787210.2025.2505559

Izumo Kanesaka, Fabian Yuh Shiong Kong, Thibaut Vanbaelen, Sheeba Santhini Manoharan-Basil, Chris Kenyon

{"title":"An overview of potential combinations therapies with ceftriaxone as a treatment for gonorrhea.","authors":"Izumo Kanesaka, Fabian Yuh Shiong Kong, Thibaut Vanbaelen, Sheeba Santhini Manoharan-Basil, Chris Kenyon","doi":"10.1080/14787210.2025.2505559","DOIUrl":"https://doi.org/10.1080/14787210.2025.2505559","url":null,"abstract":"Introduction: Ceftriaxone is the last available single dose therapy for gonorrhea that effectively treats infections at all sites. Over a quarter of isolates are now resistant to ceftriaxone in some countries. The introduction of carefully chosen combination therapy with ceftriaxone could retard the emergence of ceftriaxone resistance.Areas covered: This review summarizes the findings of a PubMed search on the use of partner antimicrobial that could be used with ceftriaxone to prevent the emergence and spread of ceftriaxone resistance. We review 16 antimicrobials that could be partnered with ceftriaxone in terms of pharmacokinetic and pharmacodynamic compatibilities, activity against ceftriaxone resistant isolates and probability of antimicrobial resistance emerging.Expert opinion: Of these 16 antimicrobials, we reject antimicrobials such as fosfomycin due to poor clinical efficacy and tigecycline due to its considerably longer half-life which would likely select for tetracycline resistance. The most promising agents for combination with ceftriaxone are zoliflodacin, delafloxacin, sitafloxacin, eravacycline and possibly gepotidacin and gentamicin. Clinical studies should be conducted to evaluate the efficacy of these combinations on the eradication of N. gonorrhoeae and their impact on AMR in N. gonorrhoeae and other bacterial species.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can probiotics replace antibiotics? Not yet, says the evidence. 益生菌能代替抗生素吗？证据表明，还没有。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-14 DOI: 10.1080/14787210.2025.2499485

Jan Łukasik, Hania Szajewska

引用次数: 0

Multi drug-resistant tuberculosis: where should we be with optimal treatment? 耐多药结核病：我们应该在哪里获得最佳治疗？

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-13 DOI: 10.1080/14787210.2025.2506777

Emanuele Pontali, Rosella Centis, Lia D'Ambrosio, Denise Rossato Silva, Daria Podlekareva, Giovanni Battista Migliori

引用次数: 0

Letter to the editor regarding "Alternative drugs for the treatment of gonococcal infections: old and new" Expert Review of Anti-infective Therapy. 2024. 22(9):753-759. 关于“治疗淋球菌感染的替代药物：新旧”的致编辑信抗感染治疗专家评论。2024。22日(9):753 - 759。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-08 DOI: 10.1080/14787210.2025.2502799

Alison Luckey, David Altarac, Sarah M McLeod

引用次数: 0

Challenges in preserving antibiotic effectiveness: time for a novel approach. 保持抗生素有效性的挑战：是时候采用新方法了。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-06 DOI: 10.1080/14787210.2025.2499472

Ashley Collazo, Larissa Grigoryan, Aanand D Naik, Barbara W Trautner

引用次数: 0

Incidence and predictors of linezolid-associated thrombocytopenia in critically ill patients: nomogram development based on comprehensive screening of over 70 factors. 危重患者利奈唑胺相关血小板减少症的发病率和预测因素：基于70多种因素综合筛选的线图发展

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-05 DOI: 10.1080/14787210.2025.2500589

Abdel-Hameed Ebid, Mohamed Abdeltawab, Osama Ahmed, Mohamed A Mobarez, Mahmoud Ibrahim

{"title":"Incidence and predictors of linezolid-associated thrombocytopenia in critically ill patients: nomogram development based on comprehensive screening of over 70 factors.","authors":"Abdel-Hameed Ebid, Mohamed Abdeltawab, Osama Ahmed, Mohamed A Mobarez, Mahmoud Ibrahim","doi":"10.1080/14787210.2025.2500589","DOIUrl":"https://doi.org/10.1080/14787210.2025.2500589","url":null,"abstract":"Background: Linezolid-associated thrombocytopenia (LAT) is a significant complication in intensive care unit (ICU) patients, increasing bleeding risk and leading to treatment discontinuation. This study aims to assess LAT incidence, identify risk and protective factors, and develop a predictive nomogram.Research design and methods: This retrospective cohort study included 422 adult ICU patients treated with linezolid. Over 70 clinical, demographic, laboratory, and therapeutic variables were analyzed. Logistic regression identified key risk and protective factors for LAT, and a nomogram was developed for risk prediction.Results: LAT occurred in 39.8% of patients. Risk factors included linezolid therapy > 10 days (OR 5.80, p < 0.01), solid organ tumor (OR 2.18, p = 0.03), hemodialysis (OR 5.12, p < 0.01), elevated lactate (OR 1.13, p = 0.03), and vasopressor use (OR 4.48, p < 0.01). Protective factors were surgery (OR 0.34, p < 0.01), IV N-acetylcysteine (OR 0.12, p < 0.01), oral N-acetylcysteine (OR 0.17, p < 0.01), higher baseline platelets (OR 0.79, p = 0.05), and acetaminophen (OR 0.42, p < 0.01). The nomogram showed strong discrimination (AUC 0.834, p < 0.001).Conclusions: LAT is common in ICU patients and associated with adverse outcomes. Prolonged therapy, solid organ tumors, dialysis, high lactate, and vasopressor use increase risk; high platelet counts, N-acetylcysteine, and IV acetaminophen decrease risk. External validation and prospective trials are warranted.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":4.2,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The ongoing challenge of prevention of pertussis in infants: what's new in 2024? 预防婴儿百日咳的持续挑战：2024年有什么新进展？

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-09 DOI: 10.1080/14787210.2025.2476010

Maria Gabriella Matera, Carlo Capristo, Vito de Novellis, Mario Cazzola

{"title":"The ongoing challenge of prevention of pertussis in infants: what's new in 2024?","authors":"Maria Gabriella Matera, Carlo Capristo, Vito de Novellis, Mario Cazzola","doi":"10.1080/14787210.2025.2476010","DOIUrl":"10.1080/14787210.2025.2476010","url":null,"abstract":"Introduction: Pertussis, a respiratory disease caused primarily by Bordetella pertussis, is undergoing a resurgence despite decades of high rates of vaccination. The prevention of pertussis in infants presents several challenges, including the waning immunity of the acellular pertussis (aP) vaccine, the limited protection afforded to newborns before they complete the vaccine series, and the existence of gaps in maternal vaccination. Furthermore, the unwillingness or refusal of a considerable number of individuals, including some healthcare workers, to receive vaccinations represents another significant challenge.Areas covered: This narrative review provides an updated overview of the ongoing challenge of preventing pertussis in infants and discusses some possible solutions.Expert opinion: The ongoing challenge of preventing pertussis in infants is multifaceted. To address these challenging issues, a multi-pronged approach is required. This approach should be designed to address various barriers and increase uptake. It should include measures to strengthen maternal vaccination programs, ensure timely infant vaccinations, improve public education, and continue research into more effective vaccines with longer-lasting immunity.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"247-263"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of bacterial spectrum and construction of a predictive model for postoperative sepsis in patients with upper urinary calculi and positive urinary cultures. 上尿路结石和尿培养阳性患者术后脓毒症的细菌谱分析和预测模型的构建。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-27 DOI: 10.1080/14787210.2025.2484285

Yizhou Wang, Meng Gao, Minghui Liu, Jinbo Chen, Zewu Zhu

{"title":"Analysis of bacterial spectrum and construction of a predictive model for postoperative sepsis in patients with upper urinary calculi and positive urinary cultures.","authors":"Yizhou Wang, Meng Gao, Minghui Liu, Jinbo Chen, Zewu Zhu","doi":"10.1080/14787210.2025.2484285","DOIUrl":"10.1080/14787210.2025.2484285","url":null,"abstract":"Background: To analyze bacterial profiles, antibiotic resistance, and urosepsis risk factors in urine culture-positive (UC+) patients post-endoscopic lithotripsy.Research design and method: Retrospectively, 806 UC+ patients (2016.3-2021.3) were stratified into urosepsis/non-urosepsis groups per Sepsis-3 criteria.Results: Among 845 isolates (56 species), Escherichia coli dominated (46.8%), followed by Enterococcus faecalis (8.8%). Gram-negative bacteria exhibited high resistance to ampicillin, cefazolin, and cefuroxime. Multivariate analysis identified preoperative multidrug-resistant (MDR) bacteriuria (OR = 2.15), staghorn calculi (OR = 2.23), days of preoperative antibiotics use <3 (OR = 1.87), absence of nephrostomy (OR = 2.30), and postoperative WBC > 9.8 × 109/L (OR = 2.69) as independent sepsis predictors. A nomogram incorporating these factors achieved robust predictive accuracy. Preoperative antibiotic use for ≥3 days was inversely correlated with the risk of urinary sepsis as the duration of antibiotic administration increased.Conclusions: Urosepsis incidence was 13.1% post-lithotripsy. Early risk stratification, targeted infection control, and antibiotic stewardship guided by urine susceptibility testing are critical for prevention.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"315-322"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review. MDRO感染时代的抑制性抗生素治疗（SAT）：叙述性回顾。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-04 DOI: 10.1080/14787210.2025.2473077

Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione

{"title":"Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review.","authors":"Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione","doi":"10.1080/14787210.2025.2473077","DOIUrl":"10.1080/14787210.2025.2473077","url":null,"abstract":"Introduction: Antibiotics were originally developed to treat acute bacterial infections, and research studies focus their efforts on safety and efficacy in the short term; however, prolonged course of antibiotics has been documented in multiple clinical settings. The aim of this narrative review is to provide a new perspective on SAT and to discuss new therapeuticpossibilities.Areas covered: We discuss new clinical scenarios in which SAT could be considered. We provided a broad discussion about long-acting agents and new or repurposed oral agents as well as the use of OPAT with elastomeric pumps and an overview of the pipeline of new antifungals. Limitations of SAT are presented in this review and especially patients' adherence issues, possible spread of MDROs, possible rising of the incidence of Clostridioides difficile infections, drug-to-drug interactions and drug-related problems, cost-effectiveness evaluation issues.Expert opinion: Many research gaps are evident and further studies are needed. Above all, the efficacy and safety of SAT in the different clinical scenarios. Discovery of new molecules against MDROs and ongoing research on PK/PD variables as well as a better understanding of the relationship between SAT and the emergence of resistance could improve SAT usage and reduce the impact of DRPs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"291-303"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0